Best Life Sciences Companies in Georgia, United States

Developer of rhenium-based implants for spine surgeries. The company has developed a MoRe, a proprietary molybdenum-rhenium superalloy for medical implants. This system can be used in adult spine deformity constructs.

Developer of medical device solutions for womens healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients’ fallopian tubes; and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. It offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening.

Funding rounds

• Nov 2025Post IPO$8M
• Jun 2025Post IPO$1.4M
• Nov 2023Post IPO$6.8M
• Jan 2017Series C$4M

Founders & team

Kathy Lee-SepsickPresident & CEO (Founder)

Investors

Legacy Capital, Salem Partners, PharmaCyte Biotech, Percy Capital

Tech stack

Apple Icloud MailCart FunctionalityCloudflareCloudflare Rocket LoaderCore-JsElementor

OXOS Medical is a developer of orthopedic imaging devices and software. The company has developed a handheld fluoroscopy device called Micro C that enables surgeons and physicians to capture images of the extremities for orthopedic procedures.

Funding rounds

• Dec 2025Series A$10.7M
• Apr 2023Series A$23M
• Feb 2022Series A$8.2M
• Feb 2021Series A$4.4M

Founders & team

Evan RuffCEO

Investors

Parkway VC, Intel Capital, FedTech, MedTech Innovator, Chang Robotics Fund

Tech stack

AdrollAdroll Cmp SystemApple Icloud MailCallrailCdnjsCloudflare

Developer of drugs to treat RNA viruses. The lead product of the company ALT-2023 is a broadly active nucleoside analog to address most Enteroviruses & Flaviviruses. Other drug candidate includes Vapendavir a capsid inhibitor with potent activity across Rhinovirus, Influenza, and Respiratory Syncytial Virus (RSV).

Funding rounds

• Feb 2026Series B$75M
• Dec 2022Series B$35M

Founders & team

John ClericiCo-FounderSeth RudnickCo-FounderGeorge PainterCo-Founder

Investors

Forbion, Sanofi, Medicxi, Pitango, Atlantic Partners, GRA Venture Fund

Developer of a neural exosome platform to design therapeutics for the treatment of neurodegenerative diseases. The platform develops neural exosomes to cross the blood-brain barrier and enhance the body's anti-inflammatory, self-repair, and protective mechanisms to treat a range of neurodegenerative disorders. The lead candidate drug AB126 is developed to treat stroke, Parkinson's, and multiple sclerosis

Funding rounds

• Aug 2025Grant (prize money)$400K
• Jun 2022Grant (prize money)$679.4K
• Apr 2021Series B$10.8M
• Sep 2019Grant (prize money)$4.5M

Founders & team

Steven SticeCo-Founder Chief Scientific Officer

Investors

Eshelman Ventures, NIH SBIR/STTR, HHS, NIEHS, Evolution VC Partners, Georgia Research Alliance

Lectenz Biosis engaged in the discovery, detection, and analysis, of glycan biomarkers of significance. The company uses their proprietary technology for the discovery called Lectenz and GlycoSense technology platforms. Lectenz reagents are engineered from a carbohydrate-processing enzyme, forming a suite of the novel and highly specific reagents for glycan detection and/or enrichment and GlycoSense technology measures binding between glycans and glycan-specific reagents conjugated to multiplex microspheres using flow cytometry, These technologies enhance the glycoprofiling workflow.

Funding rounds

• Sep 2025Grant (prize money)$2.3M
• Jul 2025Grant (prize money)$2M
• Jul 2025Grant (prize money)$313.8K
• Sep 2023Grant (prize money)$2M

Founders & team

Robert WoodsPresidentLori YangCo-Founder

Investors

Georgia Research Alliance, NIH, HHS, JLABS

Tech stack

WordpressMysqlPhpWoocommerceNinja FormsMailchimp For Woocommerce

Provider of a medical devices for post-surgical and trauma incision care. The company offers BRIJJIT is a force-modulating tissue bridge to relieve tension around incisions, supporting beautiful healing and reducing wound complications.

Funding rounds

• Jan 2026Seed—
• Feb 2025Seed$1.2M
• Dec 2023Seed$5.6M

Founders & team

Felmont EavesFounder & CMOTim GleesonCEO

Investors

Tim Gleeson

Tech stack

American ExpressApple PayCart FunctionalityCloudflareCore-JsFlickity

Developer of non-invasive electrophysiology devices to monitor peripheral nerves. The company is developed a multielectrode array-based technology that uses proprietary algorithms to test peripheral nerve activity.

Funding rounds

• May 2025Grant (prize money)$3.9M
• Mar 2025Grant (prize money)$2.1M
• Sep 2023Grant (prize money)$1.9M
• Sep 2022Series B$9M

Founders & team

Michelle JarrardCEO & President

Investors

NIH, Masters Capital Management, GRA Venture Fund, Alsora Capital, HHS, Georgia Research Alliance

Developer of immunotherapeutics for cancer treatment. It offers a lead candidate GEN-1 DNA-based immunotherapy for ovarian cancer. It has TheraPlas platform for developing anti-cancer nucleic acid-based therapies and a PLACCINE platform for developing nucleic acid vaccines for infectious diseases and cancer.

Funding rounds

• May 2025Post IPO$3.3M
• Aug 2024Post IPO$10M
• Jun 2015Post IPO$5.1M
• Jun 2014Post IPO$8.5M

Founders & team

Corinne GoffCEO

Investors

HHS

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Provider of process analytical technologies for advanced biomanufacturing. The company's flagship product is DynaCHIP, drops into existing mass spectrometry workflows that enables sample preparation exponentially. It also offers DynaMARK, which incorporates a data science module to generate on-demand measurements of the most important metrics for modern biopharma workflows.

Funding rounds

• Oct 2025Series A$5M
• 2025Grant (prize money)—
• Mar 2024Series A$3.6M
• Mar 2022Seed$500K

Founders & team

Andrei FedorovCo-FounderAndrei FedorovCo-Founder

Investors

Y Combinator, NIH, MDS Studio, Phase Two Ventures

Developer of monoclonal antibodies for multiple diseases. It offers monoclonal Variable Lymphocyte Receptors antibodies for targeting plasma cell-restricted cell surfaces to treat multiple myeloma, autoimmune disease, and transplant rejection. It also provides polymeric antibody diagnostic reagents that target the detection of infectious agents and biomedical research reagents.

Developed microneedle patch technology for vaccines and drug delivery. The patch targets skin with minimally invasive microneedle penetrates the upper layers of skin and dissolves rapidly.